Table 2.
Classification of all-cause hospitalizations as COVID-19-specific hospitalizations (N = 247) or non-COVID-19-specific hospitalizations (N = 73).
| Total | By vaccination status | By time elapsed between breakthrough infection and admission | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Boosted | Vaccinated, not boosted | Not vaccinated | Status unclear | p-value for COVID-specific versus non-specific* | Hospitalized 0–15 days | Hospitalized 16–30 days | p-value for COVID-specific versus non-specific | ||
| Overall | 300 | 69 | 99 | 127 | 5 | 280 | 20 | ||
| COVID-19-specific hospitalizations | |||||||||
| All | 226 (75.3) | 41 (59.4) | 73 (73.7) | 108 (85.0) | 4 (80.0) | < 0.001 | 217 (77.5) | 9 (45) | 0.003 |
| COVID-19 pneumonia | 147 (65.0) | 26 (63.4) | 40 (54.8) | 79 (73.1) | 2 (50.0) | 145 (66.8) | 2 (22.2) | ||
| Cardiovascular events | 23 (10.2) | 3 (7.3) | 10 (13.7) | 9 (8.3) | 1 (25.0) | 22 (10.1) | 1 (11.1) | ||
| Weakness/falls | 12 (5.3) | 2 (4.9) | 6 (8.2) | 3 (2.8) | 1 (25.0) | 11 (5.1) | 1 (11.1) | ||
| COPD/asthma exacerbation | 8 (3.5) | 4 (9.8) | 0 (0.0) | 4 (3.7) | 0 (0.0) | 7 (3.2) | 1 (11.1) | ||
| Neurocognitive disorders | 8 (3.5) | 1 (2.4) | 4 (5.5) | 3 (2.8) | 0 (0.0) | 7 (3.2) | 1 (11.1) | ||
| Gastrointestinal illness | 8 (3.5) | 0 (0.0) | 4 (5.5) | 4 (3.7) | 0 (0.0) | 7 (3.2) | 1 (11.1) | ||
| Other | 6 (2.7) | 2 (4.9) | 4 (5.5) | 0 (0.0) | 0 (0.0) | 6 (2.8) | 0 (0.0) | ||
| Thromboembolic events | 4 (1.8) | 1 (2.4) | 2 (2.7) | 1 (0.9) | 0 (0.0) | 4 (1.8) | 0 (0.0) | ||
| Isolation/observation for COVID 19 | 4 (1.8) | 1 (2.4) | 0 (0.0) | 3 (2.8) | 0 (0.0) | 4 (1.8) | 0 (0.0) | ||
| Kidney disease | 3 (1.3) | 1 (2.4) | 1 (1.4) | 1 (0.9) | 0 (0.0) | 2 (0.9) | 1 (11.1) | ||
| Non-COVID infectious disease | 3 (1.3) | 0 (0.0) | 2 (2.7) | 1 (0.9) | 0 (0.0) | 2 (0.9) | 1 (11.1) | ||
| Non-COVID-19-specific hospitalizations | |||||||||
| All | 74 (24.7) | 28 (40.6) | 26 (26.3) | 19 (15.0) | 1 (20.0) | 63 (22.5) | 11 (55.0) | ||
| GI illness | 17 (23.0) | 9 (32.1) | 5 (19.2) | 3 (15.8) | 0 (0.0) | 13 (20.6) | 4 (36.4) | ||
| Mental illness or substance abuse | 16 (21.6) | 3 (10.7) | 6 (23.1) | 7 (36.8) | 0 (0.0) | 13 (20.6) | 3 (27.3) | ||
| Non-COVID infectious disease | 15 (20.3) | 8 (28.6) | 4 (15.4) | 2 (10.5) | 1 (100.0) | 14 (22.2) | 1 (9.1) | ||
| Cardiovascular events | 6 (8.1) | 2 (7.1) | 2 (7.7) | 2 (10.5) | 0 (0.0) | 6 (9.5) | 0 (0.0) | ||
| Pain syndrome | 6 (8.1) | 2 (7.1) | 2 (7.7) | 2 (10.5) | 0 (0.0) | 6 (9.5) | 0 (0.0) | ||
| Genitourinary illness | 5 (6.8) | 2 (7.1) | 1 (3.8) | 2 (10.5) | 0 (0.0) | 4 (6.3) | 1 (9.1) | ||
| Other | 4 (5.4) | 1 (3.6) | 2 (7.7) | 1 (5.3) | 0 (0.0) | 4 (6.3) | 0 (0.0) | ||
| Neurocognitive disorders | 2 (2.7) | 0 (0.0) | 2 (7.7) | 0 (0.0) | 0 (0.0) | 2 (3.2) | 0 (0.0) | ||
| Oncology | 2 (2.7) | 1 (3.6) | 1 (3.8) | 0 (0.0) | 0 (0.0) | 1 (1.6) | 1 (9.1) | ||
| Kidney disease | 1 (1.4) | 0 (0.0) | 1 (3.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (9.1) | ||
*More details of these diagnoses are described in the Supplement.